Core Insights - Southbound capital has been a significant source of inflow into the Hong Kong stock market, with a cumulative net inflow exceeding 1.27 trillion HKD this year, marking a historical high for annual net inflows [1] - The innovative drug, technology, and non-bank sectors have seen substantial gains, with respective year-to-date increases of 79%, 53%, and 34%, compared to a 26% rise in the Hang Seng Index [1] - The largest Hong Kong innovative drug ETF (513120) received a net inflow of 585 million HKD in a single day, bringing its total size to 23.7 billion HKD [1] Fund Flows - The total net inflow for all ETFs in the market exceeded 3.777 billion HKD, with significant inflows into non-bank financials, innovative drugs, and technology sectors [1] - GF Fund Management led all public institutions with a total net inflow of 1.997 billion HKD across its ETFs, including those focused on A-shares and other sectors [2] - Notable ETFs under GF Fund Management include the innovative drug ETF (515120), low-fee创业板 ETF (159952), and the largest media ETF (512980), each receiving over 100 million HKD in net inflows [2] Market Outlook - Market volatility has increased entering November, with industry experts suggesting that fundamental improvements in 2026 may drive further gains in the Hong Kong stock market [2] - The AI industry is expected to catalyze improvements in net asset return rates (ROE) for sectors represented by the Hang Seng Technology Index, potentially leading to higher market valuations [2] - In terms of asset allocation, while the technology sector remains favorable, innovative drugs, non-bank financials, and certain cyclical assets are also worth attention [2]

Group 1 - The core viewpoint of the articles highlights the strong performance of the innovative drug sector in both A-share and Hong Kong markets, driven by policy support and market expectations for industry upgrades and technological breakthroughs [1][2]. - The Hong Kong Innovative Drug ETF (513120) has seen a year-to-date increase of over 50%, indicating significant market interest and investment in the innovative drug sector [1]. - Recent policy enhancements in medical insurance and the acceleration of the internationalization of domestic innovative drugs have contributed to the sustained growth and optimism in the industry [1][2]. Group 2 - The market is shifting towards growth sectors, with innovative drugs being a key focus due to their combination of policy support and technological barriers [2]. - The Hong Kong Innovative Drug ETF (513120) and the Innovative Drug ETF (515120) provide investors with convenient tools to invest in high-quality innovative drug companies in their respective markets [2]. - The pharmaceutical sector has experienced a prolonged adjustment period, resulting in relatively low overall valuations, which may lead to a recovery in the market [2]. Group 3 - The Hong Kong Innovative Drug ETF (513120) has a scale of 99 billion, with an average daily trading volume exceeding 23 billion, making it the top performer in its category [3]. - The year-to-date increase for the Hong Kong Innovative Drug ETF is 48.60%, while the A-share Innovative Drug ETF has increased by 13.80% [3]. - The driving factors for the sector include valuation recovery and the strengthening of domestic alternatives, with a projected improvement in payment conditions under supportive policies for commercial insurance development [3].